The Medicines Company | Date: 2014-02-06
Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
The Medicines Company | Date: 2013-10-09
Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y
The Medicines Company | Date: 2014-04-15
Methods for the treatment and prevention of bacterial skin infections using the glycopeptide antibiotic oritavancin are disclosed.
The Medicines Company | Date: 2014-05-05
A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding.
The Medicines Company | Date: 2013-12-10
Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of